22423-26-3
Chemical Structure
TK-112690
- CAS No.: 22423-26-3
- Formula:C10H12N2O5
- Molecular Weight:240.21
IUPAC Name: (2R,3R,3aS,9aR)-3-hydroxy-2-(hydroxymethyl)-7-methyl-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5]oxazolo[3,2-a]pyrimidin-6-one
InChIKey: WLLOAUCNUMYOQI-JAGXHNFQSA-N
SMILES: CC(C1=O)=CN(C2=N1)[C@@]3([H])[C@](O2)([H])[C@@](O)([H])[C@@](O3)([H])CO
Biological Activity: TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
TK-112690 | 99.91% | TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Strefeler A, et al. Nucleosides are overlooked fuels in central carbon metabolism. Trends Endocrinol Metab. 2024 Apr;35(4):290-299. [Content Brief]
- [2]. William A. Garland, et al. Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same. US 9,382,287 B2. United States Patent and Trademark Office (USPTO). Jul. 5, 2016.
- [3]. William A. Garland, et al. Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease. US 2025/0222000 A1. United States Patent and Trademark Office (USPTO). Jul. 10, 2025.
